

Abstract

The invention relates to antibodies to T cells as therapeutics.

The object underlying the invention is to provide antibodies for a clinical therapy for prolonging the immunosuppressive antibody effect while avoiding the formation of anti-antibodies.

This object is achieved by providing antibodies consisting of at least two different groups which are applied at different times and in which at least one antibody of group B differs from one antibody of group A in the constant regions of its heavy chains and wherein group A, which is first applied once or several times, has a T-cell eliminating effect, while the other group B (which is applied at a different time) has a T-cell eliminating and/or T-cell antigen modulating effect.